RPRX.US Royalty Pharma Plc

Healthcare Pharmaceuticals USA Stocks
88.69 USD
Close of Nov 18, 2026
36.68 70.13
Market cap
USD 39.5B
P/E
44.9x
P/B
4.46x
ROE
8.9%
Dividend yield
0.96%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is RPRX.US undervalued?

Graham number
Price88.69
Graham value29.72
Premium198.4%

RPRX.US trades 198.4% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Royalty Pharma Plc fundamental analysis

No fundamental analysis for Royalty Pharma Plc yet.

Royalty Pharma Plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Royalty Pharma Plc

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance t…

Full company profile